Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Xenon Pharmaceuticals Inc. (XENE)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 75,280,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 22,229 48,805 236,705 576,095
Total Sell Value $1,027,488 $2,098,369 $9,481,770 $22,449,223
Total People Sold 3 4 7 10
Total Sell Transactions 3 6 11 22
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 231
  Page 8 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Holler Frank A Director   –       •      –    2016-08-18 4 S $7.70 $73,912 D/D (9,599) 157,807     -
   Holler Frank A Director   –       •      –    2016-08-17 4 S $7.89 $12,624 D/D (1,600) 167,406     -
   Holler Frank A Director   –       •      –    2016-08-16 4 S $8.25 $56,620 D/D (6,863) 169,006     -
   Pimstone Simon N. President & CEO   •       •      –    2016-07-29 4 D $7.46 $35,084 D/D (4,703) 211,847     -
   Pimstone Simon N. President & CEO   •       •      –    2016-07-29 4 OE $3.30 $40,739 D/D 12,345 216,550     -
   Mortimer Ian CFO & COO   •       –      –    2016-06-24 4 B $6.10 $26,790 I/I 4,300 4,300 1.99     -
   Mortimer Ian CFO & COO   •       –      –    2016-06-24 4 B $6.15 $6,150 D/D 1,000 1,000 2.74     -
   Hayden Michael R Director   –       •      –    2016-05-25 4 OE $3.30 $27,159 I/I 8,230 18,518     -
   Tarnow Michael M Director   –       •      –    2016-04-28 4 GD $0.00 $0 D/D 1,543 55,167     -
   Tarnow Michael M Director   –       •      –    2016-04-28 4 OE $3.35 $5,169 D/D 1,543 56,710     -
   Robin Sherrington SVP Bus. & Corp. Development   •       –      –    2015-12-16 4 D $7.94 $1,818 D/D (229) 4,022     -
   Robin Sherrington SVP Bus. & Corp. Development   •       –      –    2015-12-16 4 OE $5.22 $2,145 D/D 411 4,251     -
   Azab Mohammad Director   –       •      –    2015-12-11 4 OE $5.22 $12,888 D/D 2,469 4,938     -
   Holler Frank A Director   –       •      –    2015-11-24 4 D $9.39 $9,343 D/D (995) 175,869     -
   Holler Frank A Director   –       •      –    2015-11-24 4 OE $5.22 $10,738 D/D 2,057 176,864     -
   Patou Gary Director   –       •      –    2015-11-04 4 D $8.32 $16,266 D/D (1,955) 4,086     -
   Patou Gary Director   –       •      –    2015-11-04 4 OE $5.22 $18,254 D/D 3,497 6,041     -
   Tarnow Michael M Director   –       •      –    2015-11-02 4 GD $0.00 $0 D/D 5,041 55,167     -
   Tarnow Michael M Director   –       •      –    2015-11-02 4 OE $5.22 $26,314 D/D 5,041 60,208     -
   Goldberg Y. Paul VP of Clinical Development   •       –      –    2015-09-24 4 S $8.60 $103,200 D/D (12,000) 6,000     -
   Goldberg Y. Paul VP of Clinical Development   •       –      –    2015-09-24 4 S $8.60 $103,200 D/D (12,000) 6,000     -
   Goldberg Y. Paul VP of Clinical Development   •       –      –    2015-09-23 4 S $9.02 $36,080 D/D (4,000) 18,000     -
   Goldberg Y. Paul VP of Clinical Development   •       –      –    2015-09-23 4 S $9.02 $36,080 D/D (4,000) 18,000     -
   Goldberg Y. Paul VP of Clinical Development   •       –      –    2015-09-22 4 S $9.33 $57,384 D/D (6,149) 22,000     -
   Goldberg Y. Paul VP of Clinical Development   •       –      –    2015-09-22 4 S $9.33 $57,384 D/D (6,149) 22,000     -
  231 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us